Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran


Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. There are some reports on quality of life in thalassemia patients around the world from southeast of Asia to Italy in Europe and United States. In this study, we tried to evaluate and compare Health Related Quality of life (HRQoL) and the health utility in beta thalassemia major patients receiving different types of iron chelators and living in different socio-economical situations.
Subjects and Methods: EQ-5D-3L accompanied by a Visual Analogue Scale (VAS) questionnaire was used. The respondents were patients with beta thalassemia major that were at least 12 years old selected from 3 provinces of Sistan-Blouchestan, Fars and Mazandaran. Comorbidities including heart complication, Diabetes Mellitus and Hepatitis and also types of iron chelators (oral, injection, combination of both) were also asked. Cross tab and ANOVA analysis conducted to evaluate each dimension score and health utility differences between provinces, iron chelation methods, comorbidities, age group and gender.
Results: 528 patients answered the questionnaires. The health utility of patients that received oral iron chelator were 0.87 ± .01 for oral iron chelators versus 0.81 ± .01 for injection dosage form (p<0.05). Increase in age was accompanied by decrease in health utility. Females faced more usual activity problems, anxiety and depression. Heart problems were more prevalent in males.
Conclusion: This study suggests that the quality of life of beta thalassemia major patients is dependent on type of iron chelation treatment which they received, the gender they have, the comorbidities they suffer and socio-economical situations they live in.

Rund D, Rachmilewitz E. β-Thalassemia. N England J Med. 2005; 353(11): 1135-46.

Abolghasemi H, Amid A, Zeinali S, et al. Thalassemia in Iran: epidemiology, preventio and management. J Pediatar Hematol Oncol. 2007; 29(4): 233-8.

Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol. 2002; 2: 3.

Maggio A, Filosa A, Vitrano A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis. 2011; 47(3):166-75.

Nadarajan VS. Modern management of thalassemia. ISBT Science Series. 2011; 6(2): 432-7.

Borgna-Pignatti, C. The life of patients with thalassemia major. Haematologica. 2010; 95(3), 345-8.

Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Expert Rev Hematol. 2011; 4(3):353-66.

Rascati K. Essentials of pharmacoeconomics. 2nd Ed. Lippincott Williams and Wilkins. 2009; p 68-71 and 112-118.

Caocci G, Efficace F, Ciotti F, et al. Health related quality of life in Middle Eastern children with beta-thalassemia. BMC Blood Disord. 2012; 12:6.

Dahlui M, Hishamshah MI, Rahman AJ, et al. Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment. Singapore Med J. 2009; 50(8): 794-9.

Sobota A, Yamashita R, Xu Y, et al. Quality of life in thalassemia: A comparison of SF‐36 results from the thalassemia longitudinal cohort to reported literature and the US norms. Am J Hematol. 2011; 86(1): 92-5.

Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther. 2007; 29(5): 909-17.

Telfer P, Constantinidou G, Andreou P, et al. Quality of life in thalassemia. Ann N Y Acad Sci. 2005; 1054(1): 273-82.

Gollo G, Savioli G, Balocco M, et al. Changes in the quality of life of people with thalassemia major between 2001 and 2009. Patient Prefer Adherence. 2013; 7: 231-6.

Haghpanah S, Nasirabadi S, Ghaffarpasand F, et al. Quality of life among Iranian patients with beta-thalassemia major using the SF-36 questionnaire. Sao Paulo Med J. 2013; 131(3):166-72.

Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005; 43(3):203-20.

Luo N, Johnson JA, Shaw JW, et al. Self-reported health status of the general adult US population as assessed by the EQ-5D and Health Utilities Index. Med Care. 2005; 43(11): 1078-86.

Robinson A, Loomes G, Jones-Lee M. Visual analog scales, standard gambles, and relative risk aversion. Med Decis Making. 2001; 21(1): 17-27.

Karnon J, Tolley K, Oyee J, et al. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Cur Med Res Opin. 2008; 24(6): 1609-21.

Keshtkaran A, Javanbakht M, Salavati S, et al. Cost–health utility analysis of oral deferasirox versus infusionaldeferoxamine in transfusion‐dependent β‐thalassemia patients. Transfusion. 2013; 53(8): 1722-9.

Osborne RH, De Abreu Lourenço R, Dalton A, et al. Quality of Life Related to Oral versus Subcutaneous Iron Chelation: A Time Trade-off Study. Value Health. 2007; 10(6): 451–6.

Safizadeh H, Farahmandinia Z, Nejad SS, et al. Quality of life in patients with thalassemia major and intermedia in kerman-iran (I.R). Mediterr J Hematol Infect Dis. 2012; 4(1): e2012058.

Goulas V, Kourakli-Symeonidis A, Camoutsis C. Comparative Effects of Three Iron Chelation Therapies on the Quality of Life of Greek Patients with Homozygous Transfusion-Dependent Beta-Thalassemia. ISRN Hematol. 2012. 2012(2012); 1-8.

Thavorncharoensap M, Torcharus K, Nuchprayoon I, et al. Factors affecting health-related quality of life in Thai children with thalassemia. BMC Blood Disord. 2010; 10:1.

Kessler RC. Epidemiology of women and depression. J Affec Disord. 2003; 74(1), 5-13.

Khani H, Majdi MR, Marzabadi EA, et al. Quality of life of Iranian beta-thalassaemia major patients living on the southern coast of the Caspian Sea. East Mediterr Health J. 2012; 18(5):539-45.

Ismail M, Choong YC, Yusoff NAM, et al. Quality of life among thalassaemia children, adolescent and their caregivers. Sains Malaysiana. 2013; 42(3): 373-80.

Gharaibeh HF, Gharaibeh MK. Factors influencing health-related quality of life of thalassaemic Jordanian children. Child Care Health Dev. 2012; 38(2): 211–8.

Musallam KM, Khoury B, Abi‐Habib R, et al. Health‐related quality of life in adults with transfusion independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Haematol. 2011; 87(1):73-9.

IssueVol 10, No 4 (2016) QRcode
Thalassemia Quality of life Health utility Iron chelators Iran

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Seyedifar M, Abedin Dorkoosh F, Hamidieh AA, Naderi M, Karami H, Karimi M, Fadaiyrayeny M, Musavi M, Safaei S, Ahmadian-Attari MM, Hadjibabaie M, Cheraghali AM, Sari AA. Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran. Int J Hematol Oncol Stem Cell Res. 2016;10(4):224-231.